The FDA on June 20, 2023, approved TALZENNA® with Enzalutamide for Homologous Recombination Repair (HRR) gene-mutated metastatic Castration-Resistant Prostate Cancer (mCRPC). TALZENNA® is a product of Pfizer, Inc.
Bottom Ad
Advertisement
Subscribe
Top Ad
Advertisement